Fundraising FoxOrbiMed — 2015 Investments
12 investments dated 2015 · listed companies and verified rows first · show all
Adicet Bio develops allogeneic gamma delta CAR T cell therapies for patients with autoimmune diseases and cancer.
BiotechHealthtechMenlo Park, US
Aya Jakobovits(Executive Officer, Director)Nathan Hubbard(Executive Officer)inChen Schor(President, Chief Executive Officer and Director)in
BoardFlorent Gros(Director)
Board seatJonathan SilversteinCarl Gordon· per SEC Form D
Co-investorsForesite CapitalPontifax Venture CapitalQuan CapitalaMoonNovartis Venture FundPureTech Health
Arvinas is a biopharmaceutical company developing PROTAC protein degrader therapies, with a pipeline focused on oncology and neurology.
BiotechHealthtechNew Haven, US
Sean Cassidy(Executive Officer)inManuel Litchman(Executive Officer, Director)inRandy Teel(President and Chief Executive Officer; Director)inCraig Crews(Founder)
BoardLiam Ratcliffe(Director)in
Board seatStephen Squinto· per SEC Form D · $55M raise · filed Apr 2018
Co-investors5AM VenturesAccess BiotechnologyCanaan PartnersConnecticut InnovationsElm Street VenturesNextech Invest+3 more
Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.
BiotechBeltsville, US
Michael Richman(Executive Officer, Director)Timothy Mayer(Executive Officer)inUdayan Guha(Executive Officer)inSteven P. Cobourn(Executive Officer)inSourav Kundu(Executive Officer)inKevin Shaw(Executive Officer)in
Board seatChau Khuong· per SEC Form D
Co-investorsBay City CapitalCanaan PartnersLAVLilly Asia VenturesPfizer Venture InvestmentsQuan Capital+4 more
Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis.
BiotechDeep TechHealthtechCambridge, US
Nessan Bermingham(Founder)inJennifer Doudna(Founder)Jose Rivera(Executive Officer)inJohn Leonard(President and Chief Executive Officer)inJames Basta(Executive Vice President, General Counsel and Corporate Secretary)inEdward Dulac(Executive Vice President, Chief Financial Officer)in
Co-investorsage1Atlas VentureAvoro Capital AdvisorsEcoR1 CapitalForesite CapitalRidgeback Capital+1 more
BiotechSan Francisco, US
Matthew Patterson(Executive Officer, Director)in
BoardSteve Squinto(Director)inKush Parmar(Director)inJonathan Leff(Director)Thomas Woiwode(Director)
Board seatJonathan Silverstein· per SEC Form D · filed Sep 2015
Co-investorsAsset Management CompanyRA CapitalvenBio Partners5AM VenturesDeerfield Management CompanyVenrock
Cerapedics develops P-15 peptide enhanced bone graft products, marketed as bone growth accelerators, for spinal fusion procedures.
BiotechHealthtechMedical DevicesWestminster, US
Andrew J. Tofe(Director)inBritt Pearson(Executive Officer)inJeff Marx(Executive Officer)inGlen Kashuba(Executive Officer, Director)inJerome Connor(Executive Officer)inAndrew Handwerker(Executive Officer)
Board seatChau KhuongJonathan Silverstein· per SEC Form D
Co-investorsRevelation PartnersNGN Capital
Rhythm Therapeutics develops precision medicines for rare neuroendocrine diseases, particularly those affecting the melanocortin-4 receptor pathway.
BiotechDigital HealthHealthtechMedical DevicesBoston, US
Keith Gottesdiener(Executive Officer, Director)inBart Henderson(Mr. Henderson is the President and Treasurer of the Issuer.)inDavid Meeker(President and Chief Executive Officer)in
BoardEdward T. Mathers(Director)inNeil Exter(Director)in
Board seatJonathan Silverstein· per SEC Form D · $40M raise · filed Dec 2015
Co-investorsForesite CapitalHEALTHCARE ROYALTY PARTNERSNew Enterprise Associates (NEA)Pfizer Venture InvestmentsWellington ManagementThird Rock Ventures
Dimension Therapeutics was a Cambridge, Massachusetts biopharmaceutical company developing AAV-based gene therapies for rare liver-associated metabolic diseases like hemophilia, OTC deficiency, and glycogen storage disease.
Cambridge, US
Annalisa Jenkins(Executive Officer, Director)
BoardBenjamin Auspitz(Director)Donald J. Hayden(Director)Allan Fox(Director)
Co-investorsF-Prime CapitalNew Leaf Venture Partners
Gelesis develops an oral superabsorbent hydrogel platform (OHS) built from naturally derived materials that works locally in the GI tract to influence satiety signals and support metabolic health.
BiotechDigital HealthHealthtechWellness & FitnessBoston, US
Yishai Zohar(Director, President, and Chief Executive Officer)inElliot Maltz(Treasurer)in
BoardJohn LaMattina(Director)Elon Boms(Director)inMeghan Fitzgerald(Director)Robert Forrester(Director)in
Co-investorsLaunchCapitalSalica InvestmentsCapstar VenturesInvescoPureTech HealthVitruvian Partners
Sikka provides integrated software for dental practices that consolidates scheduling, insurance, payments, reviews, and reporting in a single platform while automating administrative workflows like recalls and claim management.
Enterprise SoftwareHealthtechSaaS
Co-investorsMoneta VenturesSierra VenturesAramco VenturesMayfield Fund
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Clementia PharmaceuticalsIgenica Biotherapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.